Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 5,272 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Completed Phase 4 Interventional Results available

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

NCT01110200
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 85 Years
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
74
States / cities
Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Aim to Reduce Movements in Tardive Dyskinesia

NCT02195700
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
32
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 30, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

NCT01533207
View directory record Official record
Conditions
Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
Interventions
Clinical Observation, Docetaxel, Doxorubicin Hydrochloride, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim
Other · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
608
States / cities
Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 374 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Lubiprostone for Children With Constipation

NCT02138136
View directory record Official record
Conditions
Constipation - Functional
Interventions
Lubiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
67
States / cities
Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

NCT00033657
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, irinotecan hydrochloride, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
23
States / cities
Denver, Colorado • Newark, Delaware • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 30, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

NCT05179057
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Posoleucel, Placebo
Drug
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness

NCT02681081
View directory record Official record
Conditions
Pain, Osteoarthritis
Interventions
Glucose Administration, Intermittent Fasting, Control
Other
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 30, 2026, 9:57 AM EDT
Completed No phase listed Observational

The Management of Schizophrenia in Clinical Practice (MOSAIC)

NCT01746134
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Granada Hills, California • Los Angeles, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Prevention of Low Back Pain in the Military

NCT00373009
View directory record Official record
Conditions
Low Back Pain
Interventions
Traditional Army training, Core stabilization exercise only, Psychosocial education class only, Core stabilization and psychosocial education
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
4,325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Gainesville, Florida • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 30, 2026, 9:57 AM EDT
Completed No phase listed Observational

Screening in Oculopharyngeal Muscular Dystrophy

NCT02877784
View directory record Official record
Conditions
Oculopharyngeal Muscular Dystrophy
Interventions
Videofluoroscopic swallowing study, Functional Oral Intake Scale, Eating Assessment Tool-10
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness

NCT00401284
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
EVT 201
Drug
Lead sponsor
Evotec Neurosciences GmbH
Industry
Eligibility
65 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 30, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

NCT04786600
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

NCT05659264
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
mRNA-0184, Placebo
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

NCT02778399
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, OBE2109
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
71
States / cities
Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

An Emergency Department-To-Home Intervention to Improve Quality of Life and Reduce Hospital Use

NCT02079987
View directory record Official record
Conditions
ED Patients With Chronic Medical Illnesses
Interventions
ED-to-home care transition intervention, Usual Care
Behavioral · Other
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm

NCT02294175
View directory record Official record
Conditions
Lower Extremity or Diabetic Foot Ulcers, Bacterial Infection
Interventions
Larval Debridement Therapy, Bedside Sharp Debridement
Device · Procedure
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 30, 2026, 9:57 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

NCT06575192
View directory record Official record
Conditions
Breast Reconstruction
Interventions
ARTIA Reconstructive Tissue Matrix
Device
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Betaine in Patients With Nonalcoholic Steatohepatitis

NCT00586911
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Cystadane, Identical Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 30, 2026, 9:57 AM EDT
Active, not recruiting Phase 3 Interventional

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

NCT04071457
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Daratumumab/rHuPH20
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
837
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

Zenith® Low Profile AAA Endovascular Graft

NCT02535065
View directory record Official record
Conditions
Abdominal Aortic Aneurysms, Iliac Aneurysms, Aortoiliac Aneurysms
Interventions
Zenith Low Profile AAA Endovascular Graft and ancillary components
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
36
States / cities
Stanford, California • Aurora, Colorado • Hartford, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00002577
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
224
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 30, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

NCT04913675
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Anniston, Alabama • Mesa, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors

NCT00632281
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 30, 2026, 9:57 AM EDT
Completed Phase 3 Interventional

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT02500381
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SRP-4045, SRP-4053, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
6 Years to 13 Years · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 30, 2026, 9:57 AM EDT